Skip to main content

Advertisement

Table 1 therapeutic targeting of individual AML mutations

From: Molecular landscape and targeted therapy of acute myeloid leukemia

Mutation Therapeutic target Inhibitors (phase of clinical trials)
FLT3 FLT3 FLT3 tyrosine kinase inhibitors: sorafenib (III), midostaurin (approved), quizartinib (III), crenolanib (III), gilteritinib (III), lestaurtinib (III) Other TKIs: ponatinib (I/II)
IDH1/2 IDH1 Ivosidenib (approved), IDH-305(I), BAY1436032(I), FT-2102(I/II), AG-881(I)
IDH2 Enasidenib (approved), AG-881(I)
BCL-2 venetoclax (III)
KIT KIT TKIs: imatinib, dasatinib (III), ponatinib
sorafenib, sunitinib, quizartinib
TP53 TP53 PANDAS
BCL-2 venetoclax
MDM2 MDM2 inhibitors: RG7112 (I)
Others decitabine
SF3B1 SF3b complex H3B-8800 (I)
  1. MDM2 mouse double minute 2 homolog, SF3B1 splicing factor 3B subunit 1